Pharmaceutical research and developmentPharmaceutical licensing agreementsPharmaceutical salesPharmaceutical clinical trialsAdvisory services
§04
Related companies
0 COMPANIES
—
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
22 EVENTS
The journey of AskAt starting from January 2013
Established as a 100% subsidiary of Rakuoira Pharmaceutical Co., Ltd. : President Nobuyuki Koizumi : Acquired intellectual property related to the following compounds from Rakuoira Pharmaceutical: • EP4 antagonist / AAT-007, AAT-008 • 5-HT4 partial agonist / AAT-009 • COX-2 inhibitor / AAT-076
Acquired management rights from Rakuoira Pharmaceutical Co., Ltd.
Relocated headquarters to Showa-ku, Nagoya City
Akihiro Furuta appointed president : Dissolved consolidation with Rakuoira Pharmaceutical Co., Ltd. and became fully independent
Acquired intellectual property of CB2 agonist from Rakuoira Pharmaceutical Co., Ltd.
Signed a licensing agreement in China for AAT-076 and AAT-007 with RMX Co. (now Haihe Co.)
Signed a licensing agreement in China for AAT-007 with Ningbo Tai Kang Medical Technology Co.
EP4 antagonist Galliprant® began sales in the United States by Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health Co.)
Signed a worldwide (excluding China and Taiwan) licensing agreement for AAT-007 and AAT-008 with Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.)
Signed a worldwide licensing agreement for AAT-008 in the veterinary drug field with Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health Co.)
Relocated headquarters to Nakamura-ku, Nagoya City
RMX Co. (now Haihe Co.) began clinical trials of EP4 antagonist AAT-007 in the People's Republic of China
Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.) began a colorectal cancer clinical trial in the United States using AAT-007 in combination with Pembrolizumab
Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology Co.) began a Phase 1b/2 trial of AAT-007 for non‑small cell lung cancer in collaboration with Merck in the United States
Elanco Animal Health and Aratana Therapeutics Inc. launch EP4 antagonist Galliprant® in Europe
Ningbo NewBay Medical Technology Co., Ltd. begins clinical trials of EP4 antagonist AAT-007 in the oncology field in China
Oxford Cannabinoid Technologies Co. signs a worldwide licensing agreement for CB2 receptor agonist AAT-730, excluding Japan
RMX Co. (now Haihe Co.) begins clinical trials of COX-2 inhibitor AAT-076 in the pain field in China
Velo-1 Co. signs an animal drug licensing agreement for AAT-076
Aratana Therapeutics Co. (now a subsidiary of Elanco Animal Health) terminates the worldwide licensing agreement for AAT-008 in the animal drug field
Arrys Therapeutics Co. (now a subsidiary of Ikena Oncology) terminates the worldwide licensing agreement for AAT-007 and AAT-008, excluding China and Taiwan
§07
News
3 ARTICLES
AAT-730 Patent Registered in the United States
AskAt Inc. announced that the U.S. Patent and Trademark Office issued a continuation patent covering salts and crystal forms of AAT-730, a CB2 agonist, for which the company filed an application in 2021. This further strengthens the company's U.S. intellectual property rights related to AAT-730.
13th Fiscal Year Financial Results Notice Published
AskAt Inc. published its financial results notice for its 13th fiscal year on the electronic public notices page on March 23, 2026. See the page for details.
AskAt Terminates AAT-730 License Agreement
AskAt Inc. terminated its license agreement with Oxford Cannabinoid Technologies Ltd. for AAT-730, a CB2 agonist, due to a breach of contract. The company is seeking a new partner to continue development of the drug.
§08
Public records
GOV
National Tax Agency basic information6180001108273
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
株式会社AskAt
Trade name (kana)
アスカット
Name in English
Corporation type
301
Address
〒466-0064 愛知県名古屋市昭和区鶴舞1丁目2番32号
Postal code
4660064
Prefecture code
23
City code
107
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-06-13
Change date
2025-06-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
3650722
METI gBizINFO6180001108273
Source: gBizINFO (Ministry of Economy, Trade and Industry)